scholarly article | Q13442814 |
case report | Q2782326 |
P50 | author | Giuseppe Toffoli | Q54252459 |
Elena De Mattia | Q57023125 | ||
Rossana Roncato | Q57207645 | ||
Marica Garziera | Q61145262 | ||
Erika Cecchin | Q63887282 | ||
Vincenzo Canzonieri | Q72677293 | ||
Fabrizio Ecca | Q90460651 | ||
P2093 | author name string | Elena Poletto | |
Simona Scalone | |||
Giorgio Giorda | |||
Roberto Sorio | |||
Loredana Romanato | |||
Sara Gagno | |||
P2860 | cites work | Identification of a novel p53 functional domain that is necessary for efficient growth suppression | Q24311276 |
Mutation and cancer: statistical study of retinoblastoma | Q24618185 | ||
The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer | Q27824864 | ||
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. | Q27851687 | ||
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer | Q27851709 | ||
Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
Cancer statistics, 2015 | Q27860576 | ||
Structural basis for the binding of proline-rich peptides to SH3 domains | Q29620408 | ||
TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. | Q31109634 | ||
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy | Q33186850 | ||
WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study | Q33239524 | ||
Integrated analysis of germline and somatic variants in ovarian cancer. | Q33630954 | ||
Clonal evolution of chemotherapy-resistant urothelial carcinoma. | Q41315076 | ||
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. | Q41721778 | ||
TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions | Q42324763 | ||
Benign clonal keratinocyte patches with p53 mutations show no genetic link to synchronous squamous cell precancer or cancer in human skin | Q42548348 | ||
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage | Q43256441 | ||
The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells | Q43854589 | ||
Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations | Q44023983 | ||
Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer | Q44461877 | ||
Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. | Q46004659 | ||
p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer | Q46769388 | ||
Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. | Q47111129 | ||
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival | Q47773300 | ||
Recommendations for biomarker testing in epithelial ovarian cancer: a National Consensus Statement by the Spanish Society of Pathology and the Spanish Society of Medical Oncology. | Q48227450 | ||
Diagnostic Detection of Allelic Losses and Imbalances by Next-Generation Sequencing: 1p/19q Co-Deletion Analysis of Gliomas. | Q48602026 | ||
Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study | Q49337608 | ||
Metaplastic breast cancer in a patient with neurofibromatosis type 1 and somatic loss of heterozygosity. | Q49960798 | ||
Whole-genome characterization of chemoresistant ovarian cancer | Q50272478 | ||
Beyond genome-wide association studies: genetic heterogeneity and individual predisposition to cancer | Q33679037 | ||
Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes | Q34044691 | ||
p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state. | Q34060903 | ||
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci | Q34194768 | ||
Neoadjuvant chemotherapy in advanced ovarian cancer: latest results and place in therapy | Q34389383 | ||
A simple p53 functional assay for screening cell lines, blood, and tumors | Q34397902 | ||
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma. | Q34775855 | ||
Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia | Q35407650 | ||
DNA copy number variation and loss of heterozygosity in relation to recurrence of and survival from head and neck squamous cell carcinoma: a review | Q35562351 | ||
Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients | Q35906322 | ||
A Quantitative Analysis of Subclonal and Clonal Gene Mutations before and after Therapy in Chronic Lymphocytic Leukemia | Q35984259 | ||
Patterns and functional implications of rare germline variants across 12 cancer types | Q36437964 | ||
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas | Q36493279 | ||
Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing | Q36910793 | ||
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study | Q36912591 | ||
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer | Q37046405 | ||
Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer | Q37257019 | ||
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling | Q37395388 | ||
Novel BRCA1 and BRCA2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas | Q37595954 | ||
Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System | Q37611723 | ||
Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer | Q37762683 | ||
Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers | Q38087850 | ||
Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. | Q38170493 | ||
Alternative splicing in cancer: implications for biology and therapy | Q38179828 | ||
Ki67 is a promising molecular target in the diagnosis of cancer (review). | Q38266652 | ||
The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded | Q38787667 | ||
Somatic TP53 Mutations in the Era of Genome Sequencing. | Q38922539 | ||
Next-Generation Sequencing: Role in Gynecologic Cancers | Q38944589 | ||
Interaction Landscape of Inherited Polymorphisms with Somatic Events in Cancer. | Q38966664 | ||
Navigating the challenge of tumor heterogeneity in cancer therapy | Q39255308 | ||
Tumor Evolution as a Therapeutic Target | Q39448954 | ||
Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis. | Q39761795 | ||
Mistaken identity of widely used esophageal adenocarcinoma cell line TE-7. | Q40084373 | ||
Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma | Q40154485 | ||
Retention of the p53 codon 72 arginine allele is associated with a reduction of disease-free and overall survival in arginine/proline heterozygous breast cancer patients | Q40622483 | ||
The codon 72 polymorphic variants of p53 have markedly different apoptotic potential | Q40672888 | ||
Complex analysis of the p53 tumor suppressor in lung carcinoma. | Q51560589 | ||
Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma. | Q52663623 | ||
Primary versus interval debulking surgery in advanced ovarian cancer: results from a systematic single-center analysis. | Q52900611 | ||
Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. | Q53054061 | ||
Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS). | Q55259197 | ||
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods | Q57797237 | ||
LOH rather than genotypes ofTP53codon 72 is associated with disease-free survival in primary breast cancer | Q58213042 | ||
Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets | Q59357513 | ||
Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data | Q60146452 | ||
Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease | Q60683143 | ||
Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer | Q64054918 | ||
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints | Q64111448 | ||
Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods | Q77522152 | ||
Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas | Q79435490 | ||
Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis | Q80019806 | ||
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q86063198 | ||
The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer | Q87399723 | ||
Treatment resistance in urothelial carcinoma: an evolutionary perspective | Q88548676 | ||
Validation and Implementation of BRCA1/2 Variant Screening in Ovarian Tumor Tissue | Q89218812 | ||
New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach | Q92733309 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 10 | |
P921 | main subject | ovarian cancer | Q172341 |
P577 | publication date | 2019-10-01 | |
P1433 | published in | Cells | Q27724621 |
P1476 | title | Clonal Evolution of TP53 c.375+1G>A Mutation in Pre- and Post- Neo-Adjuvant Chemotherapy (NACT) Tumor Samples in High-Grade Serous Ovarian Cancer (HGSOC) | |
P478 | volume | 8 |
Search more.